دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study
doi : 10.1093/ibd/izad151
Volume 30, Issue 7, July 2024
Altered Bile Acid and Pouch Microbiota Composition in Patients With Chronic Pouchitis
doi : 10.1093/ibd/izad288
Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study
doi : 10.1093/ibd/izad147
Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis
doi : 10.1093/ibd/izad149
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study
doi : 10.1093/ibd/izad150
Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study
doi : 10.1093/ibd/izad162
Differentiation of Active Ulcerative Colitis vs Noninflammatory Bowel Disease Proctitis by Transperineal Superb Microvascular Imaging
doi : 10.1093/ibd/izad186
Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group)
doi : 10.1093/ibd/izad146
Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study
doi : 10.1093/ibd/izad156
Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes
doi : 10.1093/ibd/izad163
Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients
doi : 10.1093/ibd/izad290
Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course
doi : 10.1093/ibd/izad289
Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis
doi : 10.1093/ibd/izad178
Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis
doi : 10.1093/ibd/izad319
Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study
doi : 10.1093/ibd/izad155
Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration
doi : 10.1093/ibd/izad168
Cannabis Use in IBD Is Associated With Increased Healthcare Utilization but not With Surgery or Death
doi : 10.1093/ibd/izad164
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease
doi : 10.1093/ibd/izae078
Correspondence on: Methodological Standards When Reporting From National Databases
doi : 10.1093/ibd/izae072
On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae074
Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae079
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria
doi : 10.1093/ibd/izae043
Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients
doi : 10.1093/ibd/izad290
Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course
doi : 10.1093/ibd/izad289
Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis
doi : 10.1093/ibd/izad178
Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis
doi : 10.1093/ibd/izad319
Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study
doi : 10.1093/ibd/izad155
Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration
doi : 10.1093/ibd/izad168
Cannabis Use in IBD Is Associated With Increased Healthcare Utilization but not With Surgery or Death
doi : 10.1093/ibd/izad164
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease
doi : 10.1093/ibd/izae078
Correspondence on: Methodological Standards When Reporting From National Databases
doi : 10.1093/ibd/izae072
On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae074
Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae079
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria
doi : 10.1093/ibd/izae043
